{
  "docId": "019de073-79f3-7749-b6d9-2feecaaa4d92",
  "docSlug": "3bbd721bd246637706dab09d5c4f3165",
  "documentTitle": "Apexigen | Investor Presentation Deck | 27 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 27,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "Uses two 2x2 matrices to position competitors relative to Apexigen.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-79f3-7749-b6d9-2feecaaa4d92/11",
  "deckHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92",
  "deckJsonHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92.json",
  "deckAnchorHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.52,
        "y": 0.2
      },
      "kind": "framework",
      "text": "Clinical Stage Matrix",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "699efdbf-9b9f-4b1d-91c4-3d6a7b4ccc19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "framework",
      "text": "Antibody Design Matrix",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72a46d2e-ea89-4871-964e-0463038307ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Competitor agents grouped by quadrant; individual placement within a quadrant is not meaningful. Competitor agent notes: 1. Abbvie ABBV-927; 2. Alligator: Mitazalimab; 3. Biocytogen: YH003; 4. Celldex: CDX-1140; 5. Lyvgen 7409; 6. Roche discontinued selicrelumab but continues to work on CD40. Roche’s CD40 bispecific, RG6189, induces CD40 stimulation solely in the presence of fibroblast activation protein α (FAP) and is in a Phase 1 Tecentriq combo trial in solid tumors; 7. Rockefeller University (Jeff Ravetch) 2141-V11, an FC engineered version of selicrelumab; 8. Seagen: SEA-CD40. Other early stage CD40 antibodies, CD40L, bi-specific CD40 and gene therapy expressed CD40 antibodies are not included here.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dced992a-bc82-4af7-a806-bd8061d11436",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.8,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Sotigalimab is Differentiated from Other CD40 Agonists",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "de9e9831-fb21-4675-b627-8a4a4967e3ea",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "matrix-2x2",
      "slug": null,
      "matchId": "810d0122-cedd-4e6b-ade0-68c6c8251902",
      "evidence": "Two side-by-side 2x2 grids comparing competitors on two axes each.",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 11,
      "from": 9,
      "beatId": "bfa88b56-3bff-4ff7-bf10-cf826d73f1e6",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "Slides 9-11 present Sotigalimab as a solution, including its design and differentiation from other CD40 agonists",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "5026d18e-139d-4879-9fd9-ca4f599102e8",
      "evidence": "The solution section presents Sotigalimab as a rationally designed and differentiated CD40 agonist",
      "position": 1,
      "objective": "Why is Sotigalimab a good solution?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}